Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
SummaryAlzheimer’s disease (AD) is the most common cause of dementia and is an increasing public health problem. Because of the severity and increasing prevalence of the disease in the population, it is urgent that better treatments be developed. Active research efforts over the past several decades have produced a vast knowledge base regarding AD natural history, pathology, and key biological mediators involved in pathogenesis. As knowledge of the biomolecular mechanisms of AD has increased over the past several decades, there has been a growing consensus on the pathophysiology of the disease. These scientific advancements have led to proposals for disease-modifying therapeutic interventions that promise to significantly alter the course of AD. The translation from preclinical models to human studies requires therapeutic biomarkers to increase the likelihood of success. This review covers the current methods and technologies used in the therapeutic translation of proposed disease-modifying therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“CSF A 42 is an important biomarker for AD and has been demonstrated to be approximately 80% to 90% sensitive and specific for AD.(27,42,74) A levels change significantly over hours in younger normal participants,(75) but this normal pattern of variation may be disrupted in age or AD pathology.”
BackgroundSynaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Self-citationLacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · cited 1×
“Recent evidence has shown that plaques can form surprisingly rapidly, within 24 h, in transgenic mice and that these plaques appear to quickly stabilize in size and do not grow further.(47) This finding would seem to favor the notion that plaque formation results from a paroxysmal event, but the nature of that event i…”
BackgroundPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 7×
“Careful correlation of in vivo PiB retention with histology in autopsy samples from an AD patient who had been imaged with PiB prior to death showed that PiB binds to fibrillar A (whether in diffuse-appearing or compact plaques or cerebrovascular amyloid), but not to tau in tangles.(50) PiB does not appear to detect L…”
BackgroundInfluentialSelf-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice
Lazarov, O., Robinson, J., Tang, Y.-P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M.-Y., Hersh, L. B., Sapolsky, R. M., Mirnics, K., & Sisodia, S. S. (2005) · Cell · doi:10.1016/j.cell.2005.01.015 · Cited by 885
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Cited by
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
Self-citationCook, J. J., Wildsmith, K. R., Gilberto, D. B., Holahan, M. A., Kinney, G. G., Mathers, P. D., Michener, M. S., Price, E. A., Shearman, M. S., Simon, A. J., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1381-10.2010 · Cited by 72
Self-citation
Metadata
- Authors
- Bateman, R. J., & Klunk, W. E.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 5
- Issue
- 3
- Pages
- 381-390
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2126461396
- Cited by
- 26
- References
- 27
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. https://app.cochat.ai/papers/10.1016/j.nurt.2008.05.009
- The paper
- Bateman, R. J., & Klunk, W. E. (2008). Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. Neurotherapeutics. https://doi.org/10.1016/j.nurt.2008.05.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.